Congress : ASGCT, Washington, USA, May 2019

T-cells represent valuable tools for treatment of cancers, infectious or inherited diseases but they are mainly short-lived in vivo.  T-cell therapies would strongly benefit from gene transfer into long-lived persisting naive T cells or T-cell progenitors. During the ASGCT 2019 congress (Washington 2019), INSERM partner presented latest published data on the generation of efficient gene-corrected T-cell progenitors from SCID patients.

https://www.inserm.fr/

https://annualmeeting.asgct.org/am19/

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s